AstraZeneca Results Presentation Deck

Total Revenue ($m) 5,000 4,500 4,000 3,500 3,000 2,500 2,000 1,500 1,000 500 0 Oncology - H1 and Q2 2023 Total Revenue +22% in H1 2023 fuelled by demand growth and launch momentum Q3 2021 Oncology H1 2023 $8.8bn, +22% Q4 Q1 Q2 2022 Q3 Q4 Q1 2023 Q2 CEO Opening Remarks Tagrisso Imfinzi/Imjudo Calquence Enhertu Lynparza (PS) Lynparza milestones Others ● ● ● ● ● ● Financial Results ● Oncology BioPharmaceuticals Rare Disease Q2 2023: key dynamics CEO Closing Remarks Tagrisso +10%, strong global demand growth underpinned by ADAURA, slightly offset by NRDL price impact Lynparza PS +9%, double-digit growth in EU, EROW and EM, offset by flattening demand in 2L ovarian cancer in US Imfinzi +58%, driven by global launch acceleration (TOPAZ-1, HIMALAYA, POSEIDON) Calquence +34%, sustained BTKI class leadership Enhertu >2x, DB03/DB04 launch momentum, expanded reimbursement New indications: US (Lynparza PROpel BRCAm), CN (Enhertu DB04) capivasertib CAPItello-291 granted Priority Review in US All growth rates at CER. Collaboration partners: Daiichi Sankyo (Enhertu), Merck & Co., Inc. (Lynparza). 15 CER = constant exchange rates; NRDL= National Reimbursement Drug List; PS = Product Sales; EU = Europe; EROW= Established Rest of World; EM = Emerging Markets; BTKi = bruton tyrosine kinase inhibitor; BRCAm = breast cancer gene mutation; CN = China; DB03 = DESTINY-Breast03; DB04 = DESTINY-Breast04. 4

View entire presentation